Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 2Myeloid 2Sarcoma 1Genitourinary 1Gastrointestinal 1Classical hematology 1CNS 1Breast 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Recurrence 42Immunoglobulin Light-chain Amyloidosis 24Neoplasms 12Paraproteinemias 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Renal Insufficiency 8Amyloidosis 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Plasma Cell 6Leukemia, Myeloid, Acute 6Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia 5Burkitt Lymphoma 5Immunoproliferative Disorders 4Hodgkin Disease 4Blood Protein Disorders 4Plasmacytoma 3Peripheral Nervous System Diseases 3Neoplasms by Histologic Type 3

Interventions

Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Sorafenib 2Oxaliplatin 2Leucovorin 2Interleukin-2 2Fluorouracil 2Denosumab 2Bortezomib 2Bevacizumab 2venetoclax 1vactosertib 1trametinib 1temsirolimus 1sargramostim 1ruxolitinib 1repotrectinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Bortezomib × Plasma cell × Clear all
NCT00720785 2026-05-07

Natural Killer Cells and Bortezomib to Treat Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
35 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Neoplasm Metastasis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡